Rats were treated as neonates with either
6-hydroxydopamine (6-OHDA) 100 micrograms or vehicle intracisternally. Upon maturation, animals receiving
6-OHDA were assigned to four groups, with two of the four groups receiving intraventricular
5,7-dihydroxytryptamine (5,7-DHT) 75 micrograms bilaterally. At 94 days of age, animals were injected with either
SKF-38393 (3.0 mg/kg, intraperitoneally (i.p.)), a
dopamine D1 agonist, or
m-chlorophenylpiperazine (
m-CPP) (3.0 mg/kg, i.p.), a
5-HT2C agonist, in an attempt to evoke behaviors such as stereotypical chewing, head-nodding, self-biting and
self-mutilation. Both
SKF-38393 and
m-CPP induced the target behaviors in animals receiving
6-OHDA alone. Animals receiving additional 5,7-DHT treatment did not show any of the target behaviors in response to
SKF-38393, but exhibited a much higher sensitivity to
m-CPP. Pre-treatment with
SCH-23390 in animals receiving
6-OHDA alone was effective in preventing SKF-38393-induced target behaviors, but not those induced by
m-CPP. Pre-treatment with
mianserin partially antagonized the effects of both
SKF-38393 and
m-CPP in these same animals. In groups receiving both neonatal
6-OHDA and adult 5,7-DHT,
mianserin was effective in reducing
m-CPP-induced behaviors, while
SCH-23390 was largely ineffective. These data provide evidence of a serial relationship between the D1 and
5-HT2C receptor systems in the neostriatum of animals receiving neonatal
6-OHDA lesions.